ストックスクリーナーアプリを入手
2.40
1.64%
-0.04
前日終値:
$2.44
開ける：
$2.47
24時間の取引高:
60,681
Relative Volume:
0.34
時価総額：
$7.59M
収益：
-
当期純損益:
$-26.92M
株価収益率:
-4.7059
EPS:
-0.51
ネットキャッシュフロー:
$-18.92M
1週間 パフォーマンス:
-5.88%
1か月 パフォーマンス:
-4.38%
6か月 パフォーマンス:
-86.67%
1年 パフォーマンス:
-93.22%
1日の値動き範囲:
$2.37
$2.47
1週間の範囲:
$2.29
$2.57
52週間の値動き範囲:
$1.98
$66.60
Cel-Sci Corp. Stock (CVM) Company Profile
名前
Cel-Sci Corp.
セクター
電話
703-506-9460
住所
8229 Boone Boulevard, Suite 802, Vienna, VA
CVM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
2.40 | 7.59M | 0 | -26.92M | -18.92M | -0.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-01-13 | 開始されました | H.C. Wainwright | Buy |
| 2015-03-02 | 開始されました | Dawson James | Buy |
Cel-Sci Corp. (CVM) 最新ニュース
CEL-SCI applauds FDA approval of Merck’s Keytruda for head and neck cancer - Investing.com Canada
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients - Yahoo Finance
Two Sigma Investments LP Sells 28,248 Shares of CEL-SCI Co. (NYSE:CVM) - Defense World
CVM stock touches 52-week low at $2.32 amid sharp annual decline By Investing.com - Investing.com South Africa
CVM stock touches 52-week low at $2.32 amid sharp annual decline - Investing.com Australia
CEL-SCI Closes $5 Million Public Offering - marketscreener.com
Cancer Immunotherapy Firm CEL-SCI Secures $5M Funding to Advance Multikine Treatment - Stock Titan
CVM Stock Offering Priced Below Previous Closing Value | CVM Stock News - GuruFocus
CEL-SCI Announces Closing of Public Offering - Business Wire
Dow Moves Higher; US Initial Jobless Claims Fall - Benzinga
CEL-SCI (CVM) Prices Public Offering Amid Stock Slump - GuruFocus
CEL-SCI Prices Offering of 2 Million Shares - marketscreener.com
CEL-SCI (CVM) Prepares to Submit Breakthrough Medicine Applicati - GuruFocus
Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews
CVM Stock Offering Priced Below Previous Closing Value | CVM Sto - GuruFocus
Cel-Sci Says Prices Public Offering Of 2 Million Shares At $2.50 Per Share - marketscreener.com
CEL-SCI Raises $5M in New Stock Offering: Cancer Immunotherapy Program Multikine Gets Fresh Funding - Stock Titan
CVM stock touches 52-week low at $4.67 amid sharp annual decline By Investing.com - Investing.com South Africa
CEL-SCI Announces Planned Public Offering; Shares Fall After Hours - marketscreener.com
CEL-SCI announces public stock offering to fund cancer therapy By Investing.com - Investing.com Canada
CEL-SCI Corporation (CVM) Plans Public Offering for R&D and Corporate Needs | CVM Stock News - GuruFocus
CEL-SCI announces public stock offering to fund cancer therapy - Investing.com
CEL-SCI Announces Strategic Public Offering: Cancer Immunotherapy Development Gets Major Funding Push - Stock Titan
CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia - BioSpace
CVM stock touches 52-week low at $4.67 amid sharp annual decline - Investing.com Canada
CEL-SCI Completes Saudi Breakthrough Medicine Designation Application for Multikine Cancer Drug - marketscreener.com
CEL-SCI seeks SFDA nod for cancer drug Multikine By Investing.com - Investing.com Canada
CEL-SCI seeks SFDA nod for cancer drug Multikine - Investing.com
CEL-SCI (CVM) Prepares to Submit Breakthrough Medicine Application in Saudi Arabia | CVM Stock News - GuruFocus
Revolutionary Cancer Drug Shows 73% Survival Rate, Nears Fast-Track Approval in Saudi Arabia - Stock Titan
CEL-SCI Implements 1-for-30 Stock Split To Support Share Price - Nasdaq
CEL-SCI approves 1-for-30 stock combination By Investing.com - Investing.com South Africa
CEL-SCI (CVM) Approves 1-for-30 Stock Consolidation | CVM Stock News - GuruFocus
CEL-SCI approves 1-for-30 stock combination - Investing.com Australia
CEL-SCI's Board Approves 1-for-30 Share Combination - marketscreener.com
CEL-SCI Announces Combination of Common Stock | CVM Stock News - GuruFocus
CEL-SCI expects 1 for 30 combination of common stock to be implemented on May 20 - TipRanks
CEL-SCI Plans Major 1:30 Reverse Split as CEO Hints at Upcoming Catalysts - Stock Titan
CEL-SCI Announces Combination of Common Stock - Business Wire
StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM) - Defense World
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results | C - GuruFocus
CEL-SCI Cancer Drug Shows 95% Quality of Life Success in Phase 3 Trial | CVM Stock News - Stock Titan
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results - Business Wire
Cel-Sci: Fiscal Q2 Earnings Snapshot - New Haven Register
CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World
CEL-SCI Co. (NYSE:CVM) Shares Sold by Geode Capital Management LLC - Defense World
LD Micro 360 Companies --Set to Present this Week. - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Take off with Cel-Sci Corp (CVM): Get ready for trading - Sete News
Top investors say Ares Management Corp (ARES) ticks everything they need - Sete News
A stock that deserves closer examination: Cel-Sci Corp (CVM) - uspostnews.com
Cel-Sci Corp. (CVM) 財務データ
収益
当期純利益
現金流量
EPS
1.11%
1.70%
大文字化:
|
ボリューム (24 時間):